{
  "id": "9f3501b229e2",
  "type": "finding",
  "topic": "Zepbound Q4 2025 revenue",
  "summary": "Eli Lilly Q4 2025 earnings released Feb 4, 2026 shows Zepbound Q4 2025 revenue of $4,261 million",
  "content": "From Eli Lilly Q4 2025 earnings release (February 4, 2026):\n\nKEY DATA POINT:\n- Zepbound Q4 2025 revenue: $4,261 million (123% YoY increase from $1,907 million in Q4 2024)\n- Full Year 2025 Zepbound revenue: $13,542 million\n\nFrom the official table:\n\"Zepbound(1) 4,261 1,907 123% 13,542 4,926 175%\"\n\nFootnote: \"(1) Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States.\"\n\nThe text also says: \"For Q4 2025, U.S. Zepbound revenue increased 122% to $4.2 billion\"\n\nHistorical quarterly data:\n- Q1 2025: $2,311.9M\n- Q2 2025: $3,381.4M\n- Q3 2025: $3,588.1M\n- Q4 2025: $4,261M (reported)\n\nVerification: Q1+Q2+Q3+Q4 = 2,312+3,381+3,588+4,261 = $13,542M (matches FY2025 total)",
  "sources": [
    "https://investor.lilly.com/static-files/f087574c-4046-4711-8a56-402266f2d424",
    "https://www.prnewswire.com/news-releases/lilly-reports-fourth-quarter-2025-financial-results-and-provides-2026-guidance-302678376.html"
  ],
  "confidence": 0.99,
  "question_id": 36653,
  "report_path": "",
  "created_at": "2026-02-06T17:17:21.972821Z"
}